Evolving of treatment options for cerebral infarction

doi:10.12998/wjcc.v12.i32.6534

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (196)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=96

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=83

Publishing Process of This Article

Item

Count

Browse

Download

Sum=10

Nov 16, 2024 (publication date) through Sep 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Cases. Nov 16, 2024; 12(32): 6534-6537
Published online Nov 16, 2024. doi: 10.12998/wjcc.v12.i32.6534

Evolving of treatment options for cerebral infarction

Qiong-Yue Cao, Zheng Li

Qiong-Yue Cao, School of Life Sciences, Jiangsu Normal University, Xuzhou 221116, Jiangsu Province, China

Zheng Li, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, Xuzhou 221116, Jiangsu Province, China

Author contributions: Cao QY contributed to analysis of data, drafting the article, and providing final approval; Li Z contributed to design of the study, revising the article, and providing final approval.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Zheng Li, PhD, Lecturer, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com

Received: June 11, 2024
Revised: July 26, 2024
Accepted: July 31, 2024
Published online: November 16, 2024
Processing time: 105 Days and 0.5 Hours

Core Tip

Core Tip: In the last few decades, the treatment of cerebral infarction (CI) has seen a dramatic evolution of pharmacological drugs. This editorial focuses on the progress in treatment options for CI. We hope that it will provide valuable information for the treatment of CI.